We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.
Health conditions and diseases that the clinical trial is designed to study and treat.
HER2 positive breast cancer is a type of breast cancer that tests positive for a protein called HER2, which promotes the growth of cancer cells. This type of cancer can be more aggressive but is treatable with targeted therapies.
Oesophageal adenocarcinoma is a type of cancer that forms in the tissues of the oesophagus, often linked to chronic acid reflux. Symptoms may include difficulty swallowing, weight loss, and chest pain.
Gastric cancer, or stomach cancer, occurs when cancer cells form in the lining of the stomach. It can be asymptomatic in early stages but may lead to symptoms like stomach pain, nausea, and loss of appetite.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
